Clinical Data BridgeBio’s achondroplasia pill shows ‘compelling’ growth and body proportionality benefit BioSpaceBridgeBio Pharma plans to file for approval in the third quarter.Rare DiseaseRead full story pharminent June 29, 2026 (Last updated: June 29, 2026) BioSpace BridgeBio Pharma plans to file for approval in the third quarter. Rare Disease Read full story Post navigation Previous: Biogen trims Apellis pipeline and R&D team after $5.6bn takeoverNext: Zymeworks cuts deal to buy Theravance for $929m in cash Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026